Is NAIL a Good ETF to Buy?
If you’re thinking about buying the NAIL ETF, this article…
Buy
59
TMO Quote, Financials, Valuation and Earnings
Last price:
$545.87
Seasonality move
:
5.51%
Day range:
$528.51 - $545.32
52-week range:
$493.30 - $627.88
Dividend yield:
0.29%
P/E ratio:
33.68x
P/S ratio:
4.88x
P/B ratio:
4.19x
Volume:
2M
Avg. volume:
1.9M
1-year change:
1.12%
Market cap:
$205.5B
Revenue:
$42.9B
EPS (TTM):
$15.95
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TMO
Thermo Fisher Scientific
|
$11.3B | $5.95 | 3.77% | 41.68% | $647.56 |
|
APDN
Applied DNA Sciences
|
$1.2M | -$0.33 | 15.3% | -93.47% | -- |
|
FONR
Fonar
|
-- | -- | -- | -- | -- |
|
PRPH
ProPhase Labs
|
$5.9M | -$0.24 | -66.29% | -3.33% | -- |
|
VCYT
Veracyte
|
$116.7M | $0.26 | 18.83% | -93.75% | $43.22 |
|
XWEL
XWELL
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TMO
Thermo Fisher Scientific
|
$537.19 | $647.56 | $205.5B | 33.68x | $0.39 | 0.29% | 4.88x |
|
APDN
Applied DNA Sciences
|
$0.24 | -- | $12.6M | -- | $0.00 | 0% | 0.28x |
|
FONR
Fonar
|
$15.34 | -- | $98.2M | 10.96x | $0.00 | 0% | 0.97x |
|
PRPH
ProPhase Labs
|
$0.73 | -- | $17.4M | -- | $0.00 | 0% | 1.06x |
|
VCYT
Veracyte
|
$43.41 | $43.22 | $3.4B | -- | $0.00 | 0% | 7.74x |
|
XWEL
XWELL
|
$1.52 | -- | $8M | -- | $0.00 | 0% | 0.20x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TMO
Thermo Fisher Scientific
|
41.89% | 0.490 | 14.92% | 1.13x |
|
APDN
Applied DNA Sciences
|
-- | 1.466 | -- | 2.83x |
|
FONR
Fonar
|
0.05% | 2.598 | 0.09% | 9.32x |
|
PRPH
ProPhase Labs
|
31.06% | -0.205 | 37.21% | 1.12x |
|
VCYT
Veracyte
|
-- | 2.147 | -- | 4.59x |
|
XWEL
XWELL
|
-- | -0.924 | -- | 1.72x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TMO
Thermo Fisher Scientific
|
$4.3B | $1.9B | 7.46% | 13.08% | 19.8% | $1.9B |
|
APDN
Applied DNA Sciences
|
$244.9K | -$3.3M | -116.43% | -116.43% | -402.32% | -$3.6M |
|
FONR
Fonar
|
$10M | $4.6M | 6.12% | 6.13% | 21.06% | -$161K |
|
PRPH
ProPhase Labs
|
-$165K | -$7.9M | -47.22% | -59.59% | -252.29% | -$4.2M |
|
VCYT
Veracyte
|
$79M | $12.7M | -0.84% | -0.84% | 14.54% | $27.7M |
|
XWEL
XWELL
|
$2.1M | -$4.6M | -71.82% | -71.82% | -54.82% | -$3.8M |
Thermo Fisher Scientific vs. Competitors
-
Which has Higher Returns TMO or APDN?
Applied DNA Sciences has a net margin of 15.38% compared to Thermo Fisher Scientific's net margin of -405.45%. Thermo Fisher Scientific's return on equity of 13.08% beat Applied DNA Sciences's return on equity of -116.43%.
Company Gross Margin Earnings Per Share Invested Capital TMOThermo Fisher Scientific40.84% $4.25 $84.4B APDNApplied DNA Sciences30.12% -$0.32 $9M -
What do Analysts Say About TMO or APDN?
Thermo Fisher Scientific has a consensus price target of $647.56, signalling upside risk potential of 20.55%. On the other hand Applied DNA Sciences has an analysts' consensus of -- which suggests that it could grow by 12379.2%. Given that Applied DNA Sciences has higher upside potential than Thermo Fisher Scientific, analysts believe Applied DNA Sciences is more attractive than Thermo Fisher Scientific.
Company Buy Ratings Hold Ratings Sell Ratings TMOThermo Fisher Scientific17 7 0 APDNApplied DNA Sciences0 1 0 -
Is TMO or APDN More Risky?
Thermo Fisher Scientific has a beta of 0.765, which suggesting that the stock is 23.483% less volatile than S&P 500. In comparison Applied DNA Sciences has a beta of 0.397, suggesting its less volatile than the S&P 500 by 60.306%.
-
Which is a Better Dividend Stock TMO or APDN?
Thermo Fisher Scientific has a quarterly dividend of $0.39 per share corresponding to a yield of 0.29%. Applied DNA Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Thermo Fisher Scientific pays 8.72% of its earnings as a dividend. Applied DNA Sciences pays out -- of its earnings as a dividend. Thermo Fisher Scientific's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios TMO or APDN?
Thermo Fisher Scientific quarterly revenues are $10.6B, which are larger than Applied DNA Sciences quarterly revenues of $813.1K. Thermo Fisher Scientific's net income of $1.6B is higher than Applied DNA Sciences's net income of -$3.3M. Notably, Thermo Fisher Scientific's price-to-earnings ratio is 33.68x while Applied DNA Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Thermo Fisher Scientific is 4.88x versus 0.28x for Applied DNA Sciences. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TMOThermo Fisher Scientific4.88x 33.68x $10.6B $1.6B APDNApplied DNA Sciences0.28x -- $813.1K -$3.3M
-
Which has Higher Returns TMO or FONR?
Fonar has a net margin of 15.38% compared to Thermo Fisher Scientific's net margin of 12.56%. Thermo Fisher Scientific's return on equity of 13.08% beat Fonar's return on equity of 6.13%.
Company Gross Margin Earnings Per Share Invested Capital TMOThermo Fisher Scientific40.84% $4.25 $84.4B FONRFonar40.24% $0.46 $158.9M -
What do Analysts Say About TMO or FONR?
Thermo Fisher Scientific has a consensus price target of $647.56, signalling upside risk potential of 20.55%. On the other hand Fonar has an analysts' consensus of -- which suggests that it could fall by --. Given that Thermo Fisher Scientific has higher upside potential than Fonar, analysts believe Thermo Fisher Scientific is more attractive than Fonar.
Company Buy Ratings Hold Ratings Sell Ratings TMOThermo Fisher Scientific17 7 0 FONRFonar0 0 0 -
Is TMO or FONR More Risky?
Thermo Fisher Scientific has a beta of 0.765, which suggesting that the stock is 23.483% less volatile than S&P 500. In comparison Fonar has a beta of 1.222, suggesting its more volatile than the S&P 500 by 22.214%.
-
Which is a Better Dividend Stock TMO or FONR?
Thermo Fisher Scientific has a quarterly dividend of $0.39 per share corresponding to a yield of 0.29%. Fonar offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Thermo Fisher Scientific pays 8.72% of its earnings as a dividend. Fonar pays out -- of its earnings as a dividend. Thermo Fisher Scientific's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios TMO or FONR?
Thermo Fisher Scientific quarterly revenues are $10.6B, which are larger than Fonar quarterly revenues of $25M. Thermo Fisher Scientific's net income of $1.6B is higher than Fonar's net income of $3.1M. Notably, Thermo Fisher Scientific's price-to-earnings ratio is 33.68x while Fonar's PE ratio is 10.96x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Thermo Fisher Scientific is 4.88x versus 0.97x for Fonar. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TMOThermo Fisher Scientific4.88x 33.68x $10.6B $1.6B FONRFonar0.97x 10.96x $25M $3.1M
-
Which has Higher Returns TMO or PRPH?
ProPhase Labs has a net margin of 15.38% compared to Thermo Fisher Scientific's net margin of -209.38%. Thermo Fisher Scientific's return on equity of 13.08% beat ProPhase Labs's return on equity of -59.59%.
Company Gross Margin Earnings Per Share Invested Capital TMOThermo Fisher Scientific40.84% $4.25 $84.4B PRPHProPhase Labs-5.25% -$0.35 $55.3M -
What do Analysts Say About TMO or PRPH?
Thermo Fisher Scientific has a consensus price target of $647.56, signalling upside risk potential of 20.55%. On the other hand ProPhase Labs has an analysts' consensus of -- which suggests that it could grow by 2437.72%. Given that ProPhase Labs has higher upside potential than Thermo Fisher Scientific, analysts believe ProPhase Labs is more attractive than Thermo Fisher Scientific.
Company Buy Ratings Hold Ratings Sell Ratings TMOThermo Fisher Scientific17 7 0 PRPHProPhase Labs0 0 0 -
Is TMO or PRPH More Risky?
Thermo Fisher Scientific has a beta of 0.765, which suggesting that the stock is 23.483% less volatile than S&P 500. In comparison ProPhase Labs has a beta of -0.304, suggesting its less volatile than the S&P 500 by 130.392%.
-
Which is a Better Dividend Stock TMO or PRPH?
Thermo Fisher Scientific has a quarterly dividend of $0.39 per share corresponding to a yield of 0.29%. ProPhase Labs offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Thermo Fisher Scientific pays 8.72% of its earnings as a dividend. ProPhase Labs pays out -- of its earnings as a dividend. Thermo Fisher Scientific's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios TMO or PRPH?
Thermo Fisher Scientific quarterly revenues are $10.6B, which are larger than ProPhase Labs quarterly revenues of $3.1M. Thermo Fisher Scientific's net income of $1.6B is higher than ProPhase Labs's net income of -$6.6M. Notably, Thermo Fisher Scientific's price-to-earnings ratio is 33.68x while ProPhase Labs's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Thermo Fisher Scientific is 4.88x versus 1.06x for ProPhase Labs. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TMOThermo Fisher Scientific4.88x 33.68x $10.6B $1.6B PRPHProPhase Labs1.06x -- $3.1M -$6.6M
-
Which has Higher Returns TMO or VCYT?
Veracyte has a net margin of 15.38% compared to Thermo Fisher Scientific's net margin of 13.08%. Thermo Fisher Scientific's return on equity of 13.08% beat Veracyte's return on equity of -0.84%.
Company Gross Margin Earnings Per Share Invested Capital TMOThermo Fisher Scientific40.84% $4.25 $84.4B VCYTVeracyte68.19% $0.19 $1.2B -
What do Analysts Say About TMO or VCYT?
Thermo Fisher Scientific has a consensus price target of $647.56, signalling upside risk potential of 20.55%. On the other hand Veracyte has an analysts' consensus of $43.22 which suggests that it could fall by -0.43%. Given that Thermo Fisher Scientific has higher upside potential than Veracyte, analysts believe Thermo Fisher Scientific is more attractive than Veracyte.
Company Buy Ratings Hold Ratings Sell Ratings TMOThermo Fisher Scientific17 7 0 VCYTVeracyte6 2 1 -
Is TMO or VCYT More Risky?
Thermo Fisher Scientific has a beta of 0.765, which suggesting that the stock is 23.483% less volatile than S&P 500. In comparison Veracyte has a beta of 1.706, suggesting its more volatile than the S&P 500 by 70.591%.
-
Which is a Better Dividend Stock TMO or VCYT?
Thermo Fisher Scientific has a quarterly dividend of $0.39 per share corresponding to a yield of 0.29%. Veracyte offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Thermo Fisher Scientific pays 8.72% of its earnings as a dividend. Veracyte pays out -- of its earnings as a dividend. Thermo Fisher Scientific's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios TMO or VCYT?
Thermo Fisher Scientific quarterly revenues are $10.6B, which are larger than Veracyte quarterly revenues of $115.9M. Thermo Fisher Scientific's net income of $1.6B is higher than Veracyte's net income of $15.2M. Notably, Thermo Fisher Scientific's price-to-earnings ratio is 33.68x while Veracyte's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Thermo Fisher Scientific is 4.88x versus 7.74x for Veracyte. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TMOThermo Fisher Scientific4.88x 33.68x $10.6B $1.6B VCYTVeracyte7.74x -- $115.9M $15.2M
-
Which has Higher Returns TMO or XWEL?
XWELL has a net margin of 15.38% compared to Thermo Fisher Scientific's net margin of -56.4%. Thermo Fisher Scientific's return on equity of 13.08% beat XWELL's return on equity of -71.82%.
Company Gross Margin Earnings Per Share Invested Capital TMOThermo Fisher Scientific40.84% $4.25 $84.4B XWELXWELL24.38% -$0.99 $14.8M -
What do Analysts Say About TMO or XWEL?
Thermo Fisher Scientific has a consensus price target of $647.56, signalling upside risk potential of 20.55%. On the other hand XWELL has an analysts' consensus of -- which suggests that it could grow by 360.53%. Given that XWELL has higher upside potential than Thermo Fisher Scientific, analysts believe XWELL is more attractive than Thermo Fisher Scientific.
Company Buy Ratings Hold Ratings Sell Ratings TMOThermo Fisher Scientific17 7 0 XWELXWELL0 0 0 -
Is TMO or XWEL More Risky?
Thermo Fisher Scientific has a beta of 0.765, which suggesting that the stock is 23.483% less volatile than S&P 500. In comparison XWELL has a beta of 2.398, suggesting its more volatile than the S&P 500 by 139.765%.
-
Which is a Better Dividend Stock TMO or XWEL?
Thermo Fisher Scientific has a quarterly dividend of $0.39 per share corresponding to a yield of 0.29%. XWELL offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Thermo Fisher Scientific pays 8.72% of its earnings as a dividend. XWELL pays out -- of its earnings as a dividend. Thermo Fisher Scientific's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios TMO or XWEL?
Thermo Fisher Scientific quarterly revenues are $10.6B, which are larger than XWELL quarterly revenues of $8.4M. Thermo Fisher Scientific's net income of $1.6B is higher than XWELL's net income of -$4.8M. Notably, Thermo Fisher Scientific's price-to-earnings ratio is 33.68x while XWELL's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Thermo Fisher Scientific is 4.88x versus 0.20x for XWELL. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TMOThermo Fisher Scientific4.88x 33.68x $10.6B $1.6B XWELXWELL0.20x -- $8.4M -$4.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
3 High Dividend Dow Jones Stocks
Thanks to surging stock prices over the past two years,…
Will American Tower Stock Recover?
The performance of the real estate investment trust, or REIT,…
Stock Ideas
Sell
42
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
59
Is NVDA Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 125x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
50
NARI alert for Jan 7
Inari Medical [NARI] is up 22.25% over the past day.
Buy
70
PDEX alert for Jan 7
Pro-Dex [PDEX] is down 10.89% over the past day.
Buy
52
ALCO alert for Jan 7
Alico [ALCO] is down 3.89% over the past day.
